Hosokawa Y, Matsuge S, Murakami Y, Satoh K, Yamakawa S, Ishigooka M, Hatakeyama H, Yamazaki S
Department of Surgery, Kin-ikyo Chuo Hospital, Sapporo, Japan.
Kyobu Geka. 1999 Jan;52(1):25-9.
From 1988 to 1997, we experienced 5 cases of the superior vena cava (SVC) replacement with expanded polytetrafluoroethylene (ePTFE) grafts combined with resection of mediastinal or pulmonary malignant tumors. Two patients had lung cancer and three had invasive thymoma. Resection and reconstruction of the superior vena cava (SVC) were performed by application of a bypass graft between the innominate vein and the right atrium in two cases and a temporary bypass using a heparin-coated tube in three cases. Except in one patient who died of acute respiratory failure, no complication or occlusive symptom were observed postoperatively. Two patients remain healthy for 5 years 4 months and 2 years 7 months after operation. Three died 9 years, 5 months, and 110 days after operation respectively. In conclusion, ePTFE graft replacement or patch angioplasty of the SVC should be part of planning and execution of radical excision with curative intent of mediastinal or pulmonary malignant tumors.
1988年至1997年期间，我们收治了5例采用膨体聚四氟乙烯（ePTFE）人工血管置换上腔静脉（SVC）并联合切除纵隔或肺部恶性肿瘤的患者。其中2例为肺癌患者，3例为侵袭性胸腺瘤患者。2例行无名静脉与右心房之间应用搭桥人工血管进行上腔静脉（SVC）切除重建，3例行使用肝素涂层管的临时搭桥。除1例死于急性呼吸衰竭外，术后未观察到并发症或闭塞症状。2例患者术后分别存活5年4个月和2年7个月，身体状况良好。另外3例分别于术后9年、5个月和110天死亡。总之，ePTFE人工血管置换或SVC补片血管成形术应作为根治性切除纵隔或肺部恶性肿瘤的计划和实施的一部分。
